RxDoctor Payments Data

Janel Hillstrom

Nurse Practitioner · Mesquite, NVNPI 1992959324

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novo Nordisk accounts for 61.6% of it on its own, with 5 other manufacturers making up the rest.

$570in general payments, 2019–2025

Across 25 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$351
  • AbbVie$110
  • Dexcom, Inc.$36
  • Johnson & Johnson$36
  • Medtronic$23
  • Eisai Inc.$14

What the payments were for

  • Food & beverage$570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$351
AbbVie6$110
Dexcom, Inc.2$36
Johnson & Johnson2$36
Medtronic1$23
Eisai Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$570 in reported general payments places this provider in the 65th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$43,067
Medicare patients
352
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide11$26,009
Albuterol Sulfate HfaAlbuterol Sulfate35$1,213
Trazodone Hcl15$593
Ibandronate Sodium18$488
Buspirone Hcl36$466
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav69$439
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst37$418
Mupirocin47$387
Rosuvastatin Calcium34$376
Omeprazole27$365
Aripiprazole13$339
Ofloxacin18$338
Gabapentin16$332
Ezetimibe11$319
Famotidine17$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$351$26,00911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Mesquite

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →